[ad_1]
OGYÉI experts visited Beijing to conduct the so-called GMP (Good Manufacturing Practice) inspection to verify the correct manufacturing conditions of pharmaceuticals at the coronavirus vaccine plant of China National Pharmaceutical Group (CNBG), a subsidiary of Sinopharm. At the factory delivered in May last year, the Hungarian experts who conducted the inspection were able to review the entire production process, as well as provide them with full documentation on production, the department head reported, praising the open attitude of the CNBG towards them. “We were able to see what we wanted,” he stressed.
When asked about the transport of the vaccine, the expert replied that the transport of the vaccine, which can be stored at a temperature between 2 and 8 degrees, can be solved by temperature control, so that safe transport can be easily guaranteed . Ferenc Lukács emphasized:
the vaccine is manufactured in a modern factory under safe conditions,
During the inspection, the Hungarian experts only commented on minor details that did not affect the quality of the preparation.
Gergely Gulyás, head of the Prime Minister’s Office, said Thursday:
the Hungarian government has practically already agreed with Sinopharm to purchase vaccines,
the date of administration of the first dose, which can be up to a million, depends on the speed of the Hungarian pharmaceutical regulatory approval.
The Sinopharm vaccine received a conditional marketing authorization in China on December 30, according to which it is used in the country between the ages of 18 and 59. The authorization was granted by the Chinese health authorities after the manufacturer declared that, based on an interim analysis of the results of the third phase of clinical trials, the drug provides protection against coronavirus infection with an effectiveness of 79.34 percent.
Cover Image Source: Getty Images
[ad_2]
